Home
overview

The SMi group are thrilled to announce their 5th Molecular Diagnostics Conference! The meeting is convening in central London on 9th-10th July 2018, with a half-day post-conference workshop on 11th July 2018.


The global molecular diagnostics market is forecast to reach over $10 Billion USD in the next three years, at a CAGR of 9.1% from 2016 to 2021*. In this ever-evolving universe of molecular diagnostics, it is vital to keep up with emerging and developing technologies, products and applications. Furthermore, companies must comply to the constantly changing regulatory environment and tackle the challenging process of implementing these regulations.
Therefore, the SMi Group welcome you to explore the expanding market opportunities, latest diagnostic advancements and regulatory requirements at the 2-day conference.


KEY THEMES FOR MOLECULAR DIAGNOSTICS 2018:

  • Regulatory changes, challenges and outlook 
  • Advances in laboratory technologies
  • Development of diagnostic techniques
  • Personalised medicine & pharmacogenomics 
  • Diagnostic methods at the point of care
  • Molecular Diagnostics in Infectious Disease and Cancer

(*The Market Report can be found here: https://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html.)
 

The Conference:

  • Analyse the latest developments in companion diagnostics and discuss the future of the industry
  • Learn what will be required in the new European In Vitro Diagnostics Regulations
  • Develop a system’s approach for immune testing and monitoring
  • Assess opportunities and novel diagnostic technologies at the point of care
  • Discuss the role of molecular diagnosis in the development of personalised medicine

Why choose SMi Events?

Networking: We keep networking at the forefront when it comes to our attendees. Expand your community with every part of the industry and with the right people to benefit your company and develop your career.

The Agenda: Be sure to have your pen and pad ready at all times! A valuable time is spent to discover the latest trends and hottest topics in the industry to provide the best possible agenda for our attendees.

Location/Venue: Being held in the heart of London, The Holiday Inn Kensington Forum, London is an elegant contemporary four-star hotel in prestigious Kensington, located just a few minutes’ walk from High Street Kensington underground station, making exploring easy. See the wonderful sights of Kensington, by visiting Kensington Palace, the historical Museums, or take a stroll in Kyoto Garden!

Onsite: Our knowledgeable events team will provide you with an exceptional service onsite. They will answer any questions you may have and inform you about any changes to the agenda.

CPD Certified: Continuing professional development (CPD) is a commitment by members to continually update their skills and knowledge in order to remain professionally competent. You can gain CPD points by attending our events! 

Attendees will primarily be drawn from the following backgrounds/departments: Molecular Diagnostic, Cancer Immunology, Immunobiology, Biomarkers, Radiation Oncology, Therapeutic Radiology, Translational Medicine, Translational Assays Technologies, Companion Diagnostics, Clinical Chemistry, Experimental Medicine and Diagnostics.

They will include Leads, Directors, Heads, Project Managers, Principal Investigators, Principal Scientists, Senior Scientists, Research Scientist, Professors, Researchers and Clinical Analysts, amongst others.
 

Past Attendees include:

Adams Business Associates; AstraZeneca; BioKit SA; Buehlmann Laboratories A G; Cambridge Isotope Laboratories Inc.; Clinica World Medical Technology News; Enigma Diagnostics Ltd; Frost & Sullivan; Future Drug Ltd; Genzyme Analytical Services; GlaxoSmithKline; Human Genetic Signatures; Imperial College London; Institute of Food Research (The); Integrated Medicines; LabCorp; Leiden Univ Medical Center; Leomics Consulting; Medical College of Wisconsin; MHRA; National Genetics Reference Lab, Manchester; Qiagen Ltd; QuantuMDx Group Ltd; Radiometer Medical APS; Roche Diagnostics Ltd; University of Edinburgh; Vivacta Ltd;

Conference programme

8:30 Registration & Coffee

9:00 Chairmen's Opening Remarks

Hugues Malonne

Hugues Malonne, Director General,, Federal Agency for Medicines and Health Products

David Crosby

David Crosby, Head of Early Detection Research, Cancer Research UK
View Bio

9:10 KEYNOTE ADDRESS: A National Competent Authority’s perspective on IVDR

Hugues Malonne

Hugues Malonne, Director General,, Federal Agency for Medicines and Health Products

• What can we do to support the transition to IVDR?
• How do we structure ourselves to address the upcoming challenges?

9:50 Quality Assessment in molecular diagnostics and advantages of two-tailed PCR

Mikael Kubista

Mikael Kubista, Professor, Czech Academy of Sciences
View Bio

• Learn how the ongoing efforts within SPIDIA and CANCER-ID to standard the preanalytical process in molecular diagnostics
• Analyse how this has led to the development of CEN, ISO and MIQE guidelines
• Discover a new, highly specific, sensitive and cost-effective system to quantify miRNA expression called Two-tailed RT-qPCR

10:30 Morning Coffee

11:00 Design & delivery of an umbrella study in bladder cancer

Darren Hodgson

Darren Hodgson, Senior Principal Scientist, Astrazeneca
View Bio

• One disease: multiple hypotheses
• Scientific and practical considerations

11:40 Progress towards the use of peripheral blood biomarkers for diagnosis of infectious disease

Karen Kempsell

Karen Kempsell, Senior Project Team Leader, Public Health England
View Bio

• Hard to diagnose infectious diseases
• Host immune cell biomarker discovery and validation
• Biomarker-based diagnostic test development

12:20 Networking Lunch

13:20 System’s Approach to Immune monitoring - A path towards establishing genetic and microbial determinants of human immune variability

Matthew Albert

Matthew Albert, Principal Scientist, Cancer Immunology, Genetech Ltd
View Bio

• Natural variation in innate immune cell parameters is driven by genetic factors
• CMV infection is a major determinant of adaptive immune phenotypes
• Age and sex shapes transcriptional variation of human immune responses

14:00 Development of multiplex graphene biosensor

Owen Guy

Owen Guy, Head of Systems Process Engineering Centre and Director, Centre for Nanohealth Engineering, Swansea University
View Bio

• Graphene devices
• Fabrication of biosensor platform including chemical modification strategies for graphene devices
• Outline of multiplex sensor platform
• Integration of graphene sensor with microfluidics and packaging technology

14:40 Afternoon Tea

15:10 Companion diagnostic assay development for RNA targeting therapeutics

Sterghios Moschos

Sterghios Moschos, Reader in Industrial Biotechnology, University of Westminster

• Personalised medicine opportunities for siRNA and antisense therapy
• Sampling bias limitations in SNP pharmacogenomics.
• A patient-free, big data, in cellulo solution to predictive pharmacogenomics
• Pathways to CLIA/IVD companion diagnostic development

15:50 Life beyond the pixels: Single-cell analysis using machine learning and image analysis methods

Peter Horvath

Peter Horvath, Group Leader, Synthetic & Systems Biology Unit and Finnish Distinguished Professor Fellow, Hungarian Academy of Sciences and Institute for Molecular Medicine Finnland

• Overview of the computational steps in the analysis of a single cell-based large-scale microscopy experiments
• Novel microscopic image correction method
• New single cell image segmentation methods
• A machine learning software tool capable of identifying cellular phenotypes based on features extracted from the image
• Recently developed single-cell isolation methods, based on laser-microcapturing
• Presenting a successfully performed DNA and RNA sequencing, dPCR

16:30 Chairmen’s Closing Remarks and Close of Day One

Hugues Malonne

Hugues Malonne, Director General,, Federal Agency for Medicines and Health Products

David Crosby

David Crosby, Head of Early Detection Research, Cancer Research UK
View Bio

8:30 Registration & Coffee

9:00 Chairmen's Opening Remarks

Hugues Malonne

Hugues Malonne, Director General,, Federal Agency for Medicines and Health Products

David Crosby

David Crosby, Head of Early Detection Research, Cancer Research UK
View Bio

9:10 Out-sourced Diagnostics Device development: When is it the smart choice

Carmelo Volpe

Carmelo Volpe, Head of Clinical Diagnostics, Cambridge Consultants Ltd
View Bio

• The right product in the right market in the shortest time keeps investors happy
• The role of sales, marketing and R&D is critical in defining the right product
• How do you know when are you ready to outsource?

9:50 Extending your UKAS accreditation

Ben  Courtney

Ben Courtney, Accreditation Manager, United Kingdom Accreditation Service
View Bio

• Extension to Scope
• Flexible Scope

10:30 How should pharma evaluate diagnostic investment opportunities?

Ruth Krestin

Ruth Krestin, Director Precision Medicine Business Insights & Policy, AstraZeneca
View Bio

• While a companion diagnostic might be required for a successful drug approval, the specific choice of technology platform, investment timing and diagnostic partner(s) can have significant commercial implications down the line.
• How can pharma companies evaluate which diagnostic investment opportunities make commercial sense?
• How do you build a business case for a diagnostic investment?
• How can diagnostic strategies and investment timings impact drug sales?

11:10 Morning Coffee

11:40 Development of a point of care aid for the rapid diagnosis of stroke

Nicholas Dale

Nicholas Dale, Ted Pridgeon Professor of Neuroscience, University of Warwick
View Bio

• Stroke is a medical emergency that requires rapid clinical decisions that can have far reaching consequences for the victim
• There is a lack of objective diagnostic tools that are sensitive and specific at the early stages of pathology when there can be the greatest benefit of intervention
• The purines are a rapidly produced biomarker of tissue ischaemia
• Sarissa Biomedical has developed a finger prick blood test for purines and has tested whether this can identify stroke victims

12:20 Proposal for an ‘on-line’ virtual clinical investigative ambulance

Ashfaq Gilkar

Ashfaq Gilkar, Clinical Analyst, Strategy and Engagement, Essentia Technology, NHS Foundation Trust
View Bio

chine within an Ambulance setting prior to entry to the hospital could help front line staff accelerate decision making, reduce congestion and most importantly, improve patient waiting times in a busy A&E department
• Connecting POCT analysers in an Ambulance to the Hospital EPR/EHR system via the London Ambulance Service is a unique, innovative approach, providing clinicians with direct electronic access to patient blood test results even before the patient arrives into the A&E dept!
• On-line POCT configuration within an Ambulance setting is robust, reliable, user friendly and can resolve staffing issues in Acute care
• Advanced Paramedics with appropriate training from the clinical laboratory will be able produce accurate and precise results
• This ‘life saving’ project will directly address the major national problem of Congestion in A&E for Ambulance patients and reduce admissions into the hospital, improving Clinical Outcomes as well as improving patient safety and data quality

13:00 Networking Lunch

14:00 Personalisation of drug treatment to minimise drug toxicity

Ana  Alfirevic

Ana Alfirevic, Reader in Pharmacology, The Wolfson Centre, University of Liverpool
View Bio

• Type A and Type B adverse drug reactions
• Genotype guided dosing of drugs
• Gene panel and clinical decision support system to minimise drug toxicity

14:40 Cancer Research UK’s strategy in early detection research – precision diagnostics to precision intervention

David Crosby

David Crosby, Head of Early Detection Research, Cancer Research UK
View Bio

• CRUK has a strategic priority in improving the early detection and diagnosis of cancers, and a strong platform of innovation and delivery in stratified/precision medicine (and the accompanying genetic diagnostics)
• CRUK is currently developing and implementing a major programme of investments in early detection of cancers, centring on precise and predictive diagnostic technologies
• A key component of this strategy is industry engagement, not only as end-users and commercialisers of academic discovery, but as intellectual partners throughout the research journey from discovery to implementation
• A number of opportunities are now open or forthcoming for companies to work with CRUK to drive discovery and translation in the early detection and molecular diagnostics space

15:20 Afternoon Tea

15:50 Precision Medicine and Healthcare

Nick Housby

Nick Housby, CEO and Director, Accunea Ltd and Precision Medicine Strategy (New Medicine Partners)
View Bio

• How close are we?
• NHS ambitions
• Genomics specialist centres
• Accunea Ltd – an example of precision clinical management of AKI

16:30 Personalised Medicine – status and future perspective

Kewal Jain

Kewal Jain, Chief Executive Officer, Jain PharmaBiotech
View Bio

• Personalised medicine remains the best concept for integrating biotechnologies to optimise the treatment of individual patients
• Molecular diagnostics and biomarkers play an important role in the development of personalised medicine
• Pharmacogenomics, pharmacogenetics, pharmacoproteomics, and metabolomics are making important contributions, but epigenetics and environmental factors are also taken into consideration in personalised medicine
• Cancer is an important area of application where genotypebased anticancer drugs are selected by companion diagnostics and tumor heterogeneity is a challenge
• Biological therapies are already being personalised and there will be further development of this approach for cell and gene therapies as well as therapies based on RNAi, miRNA, and microbiomics
• With the current interest and advances in technologies, personalised medicine is expected to become a part of the routine medical practice in the next decade

17:10 Chairmen’s Closing Remarks and Close of Day Two

Hugues Malonne

Hugues Malonne, Director General,, Federal Agency for Medicines and Health Products

David Crosby

David Crosby, Head of Early Detection Research, Cancer Research UK
View Bio

+

FEATURED SPEAKERS

Ana  Alfirevic

Ana Alfirevic

Reader in Pharmacology, The Wolfson Centre, University of Liverpool
Ashfaq Gilkar

Ashfaq Gilkar

Clinical Analyst, Strategy and Engagement, Essentia Technology, NHS Foundation Trust
Ben  Courtney

Ben Courtney

Accreditation Manager, United Kingdom Accreditation Service
Carmelo Volpe

Carmelo Volpe

Head of Clinical Diagnostics, Cambridge Consultants Ltd
Darren Hodgson

Darren Hodgson

Senior Principal Scientist, Astrazeneca
David Crosby

David Crosby

Head of Early Detection Research, Cancer Research UK
Hugues Malonne

Hugues Malonne

Director General,, Federal Agency for Medicines and Health Products
Karen Kempsell

Karen Kempsell

Senior Project Team Leader, Public Health England
Kewal Jain

Kewal Jain

Chief Executive Officer, Jain PharmaBiotech
Matthew Albert

Matthew Albert

Principal Scientist, Cancer Immunology, Genetech Ltd
Mikael Kubista

Mikael Kubista

Professor, Czech Academy of Sciences
Nicholas Dale

Nicholas Dale

Ted Pridgeon Professor of Neuroscience, University of Warwick
Nick Housby

Nick Housby

CEO and Director, Accunea Ltd and Precision Medicine Strategy (New Medicine Partners)
Owen Guy

Owen Guy

Head of Systems Process Engineering Centre and Director, Centre for Nanohealth Engineering, Swansea University
Ruth Krestin

Ruth Krestin

Director Precision Medicine Business Insights & Policy, AstraZeneca

Ana Alfirevic

Reader in Pharmacology, The Wolfson Centre, University of Liverpool
Ana  Alfirevic

I am a Reader in Pharmacology with the primary focus on pharmacogenetics and molecular pharmacology research. I have been working on several projects on identification of genetic predisposing factors for adverse drug reactions including drug-induced hypersensitivity, hepatotoxicity, antipsychotic drug-induced agranulocytosis and statin-induced myotoxicity using high throughput genotyping and sequencing technologies. Recently, I started several pharmacology and systems biology projects in reproductive medicine and pregnancy. I lead a workpackage on multiomic approaches to preterm birth within the Harris Centre for Preterm Birth funded by Wellbeing of Women. I lead the PREDICTION-ADR EU project that investigates predisposing genetic factors to statin-induced myopathy. Common to these research themes is the aim to generate large amount of multi-omics data integrated with clinical data to identify biomarkers that may be utilized in clinical practice for patient benefit.
In addition, I am involved in public health research via the National Institute of Health Research Collaboration for Leadership in Applied Health Research and Care North West Coast (CLAHRC NWC), where I am a co-lead for the Delivering Personalised Health and Care theme. The overarching aim of the programme is to tackle health inequalities. I have authored >100 peer-reviewed publications.

Ashfaq Gilkar

Clinical Analyst, Strategy and Engagement, Essentia Technology, NHS Foundation Trust
Ashfaq Gilkar

I have over 18 years' experience in Healthcare IT & healthcare sciences, having worked previously for Cancer Research UK, Imperial College and Chelsea & Westminster hospitals, London. My main expertise and area of interest lies in Clinical Analysis/Healthcare Business Analysis having worked in this field for the past 4 years at Guys and St Thomas’ NHS Foundation trust. I am currently focused on the scoping for a new EHR system to be implemented at GSTT with particular emphasis on the utilisation of medical devices and healthcare technology plus it’s application in varying clinical settings thus improving the overall patient experience. I also have vast expertise in POCT devices, with a particular focus on the connectivity aspects to maximise full utilisation and patient clinical benefits.

Ben Courtney

Accreditation Manager, United Kingdom Accreditation Service
Ben  Courtney

Ben is the Accreditation Manager for Medical Laboratories within UKAS, responsible for the day-to-day management of CPA accredited laboratories transitioning to ISO 15189, EQA Providers and POCT organisations. Ben started work as a Biomedical Scientist working in an NHS Microbiology Department and worked at various grades throughout his time in pathology before moving to UKAS in 2008. Initially, Ben worked as an Assessment Manager, leading medical and testing laboratory assessments in the UK and overseas. Ben became the Accreditation Manager in 2012 and manages a team of 28 Assessment Managers who deliver UKAS assessments to ISO 15189, ISO 17043 and ISO 17025. The transition to ISO 15189:2012 and to ISO 22870:2016 from CPA Standards has been the primary focus of work over recent years and as the transition period comes to an end, there is increasing focus on the accreditation of point of care testing and encouraging applications.

Carmelo Volpe

Head of Clinical Diagnostics, Cambridge Consultants Ltd
Carmelo Volpe

Carmelo holds a Ph.D. in Molecular Biology and a B.Sc. in Biotechnology and has over 20 years of experience in the Life Sciences with a particular focus on Point-of-Care Molecular Diagnoses. He has lead global teams and business units in both the veterinary and clinical Diagnostics markets.

He has experience of Strategic Marketing, Program Management, Product Development and Business Development from many years working with both large Life Science and smaller start-up biotechnology companies.

As head of Clinical Diagnostics his focus is to help clients differentiate themselves from their competition by developing truly world class, disruptive Clinical Diagnostic platforms and solutions by leveraging his commercial experience combined with the depth and breadth of technical expertise at Cambridge Consultants.

Darren Hodgson

Senior Principal Scientist, Astrazeneca
Darren Hodgson

Darren is senior principal translational scientist and project leader for the bladder cancer umbrella study IMED Oncology, AstraZeneca, having previously had positions in global medicine develop¬ment, academia, biotechnology, and diagnostics sectors. Darren has over 7 years’ experience as a core member of a multi-functional global product team and has been responsible for strategy, internal and external assay development, clinical deployment, and regulatory representation for bio-markers used as primary, secondary, and exploratory objectives of clinical studies in all stages of drug development. Most recently, Darren was the translational science lead for Lynparza, which is AstraZeneca’s first in class PARP inhibitor approved in 2014. This was used for ovarian cancer indications in Europe and the US, which is defined by loss of function mutations in tumour suppressor genes. Darren is the author of numerous reviews, original patents and papers, journal editor, the chairman of the Manchester Consumer Healthcare Ethics committee, and lectures at the Universities of Manchester and Leeds.

David Crosby

Head of Early Detection Research, Cancer Research UK
David Crosby

David Crosby is head of early detection research at Cancer Research UK. He began life as a baby before becoming a pharmacologist, studying cell signalling in platelets. He spent time in academia and industry (identifying and evaluating new clinical development opportunities) before joining the Medical Research Council, where he oversaw various science areas and research funding programmes, most recently leading the MRC-NIHR methodology research programme. He has worked with an array of grant and fellowship review boards and panels, and has at least a partial understanding of what they look for. He has led several strategic reviews of research areas and consequent development of new funding initiatives. He is now developing a new strategy and programme of research investments at CRUK which aims to accelerate progress towards earlier detection and treatment of cancer, which he finds to be jolly good fun.

Hugues Malonne

Director General,, Federal Agency for Medicines and Health Products
Hugues Malonne

Karen Kempsell

Senior Project Team Leader, Public Health England
Karen Kempsell

Dr Karen Kempsell is an established senior scientist in the areas of microbial genetics & pathogenesis, immunopathology and diagnostics. She has an established track record in academic and industrial R&D and twenty three years of experience in the translational research and development area. She is currently the principle investigator/scientific lead of the diagnostics section of the Technology Development group at Public Health England Porton. She has extensive experience in microbiology, clinical infectious diseases, immunopathology, molecular and systems biology, bioinformatics, molecular and serological assay development and commercial diagnostic assay development and validation. She is invited speaker at scientific conferences on development of biomarker-based diagnostics. She manages external collaborations and relationships with key customers and stakeholders. She was the principle investigator on biomarker development programmes which led to patents for diagnostic biomarkers for human tuberculosis and sepsis.

Kewal Jain

Chief Executive Officer, Jain PharmaBiotech
Kewal Jain

Prof. Kewal Jain, a neurologist/neurosurgeon, entered biotechnology and pharmaceutical medicine as a second career. He is a fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of London since 2000. He started with molecular diagnostics and wrote the first commercial report on this topic in 1995, which has remained the longest continuously published report on this topics with revisions and rewriting until now. Soon afterwards, he started to develop personalized medicine and wrote the first monograph on this topic in 1998, which evolved into single-author Textbook of Personalized Medicine, published by Springer. It is in the 2nd edition and has been translated into Japanese. Several of his 28 books include chapters on personalized medicine or cover topics relevant to personalized medicine, e.g., Handbook of Nanomedicine, 3rd ed, Springer, 2017 and Handbook of Biomarkers, 2nd ed, Springer, 2017. Both books have been translated into Chinese. Over the past 2 decades Prof. Jain has given numerous invited lectures worldwide as well as conducted workshops on personalized medicine and molecular diagnostics. Recently, he served a 2-week stint as visiting Professor of Personalized Medicine at University of Kazakhstan.

Matthew Albert

Principal Scientist, Cancer Immunology, Genetech Ltd
Matthew Albert

Matthew Albert is an Immunologist and Clinical Pathologist, with a long-standing interest in immune regulation and tumor immunity. His research embraces the power of a bedside-to-bench approach to scientific discovery, driven by a commitment to understand how to initiate effective cancer immunotherapy. As this requires a greater insight into disease pathogenesis, he has developed several clinical areas of investigation over the last decade, including: bladder cancer immunotherapy; and the immunopathogenesis of viral hepatitis and hepatocellular carcinoma. He has also taken a leadership role in co-coordinating the Milieu Intérieur Consortium, a 30-team academic / industrial partnership that aims to define the genetic and environmental determinants of variable immune responses. While it is still early days, there is now an exciting opportunity for applying the concept of standardized immunophenotyping and induced functional immune response monitoring in order to establish a path forward for personalized cancer immunotherapy. ??

Mikael Kubista

Professor, Czech Academy of Sciences
Mikael Kubista

Kubista is one of the pioneers in molecular diagnostics. He invented the light-up probes, which led to the foundation of LightUp Technologies AB as Europe´s first company focusing on qPCR based diagnostics. He co-founded MultiD Analyses AB, which develops the market leading qPCR analysis software GenEx. In 2001 Kubista set up the TATAA Biocenter as center of excellence in qPCR and gene expression analysis. TATAA biocenter was the first laboratory in Europe to obtain flexible ISO 17025 accreditation and was presented the Frost & Sullivan Award for Customer Value Leadership as Best-in-Class Services for Analyzing Genetic Material in 2013. In 2014 TATAA introduced non-invasive prenatal testing (NIPT) in Sweden founding Life Genomics AB. Kubista also co-authored the MIQE guidelines and he is member of the CEN/ISO working groups developing guidelines for the pre-analytical process in molecular diagnostics. Most recently Kubista’s team invented Two-tailed PCR, which is currently the most sensitive and specific method for microRNA analysis. Since 2007 Kubista heads the Department of Gene Expression at the institute of Biotechnology of the Czech Academy of Sciences.

Nicholas Dale

Ted Pridgeon Professor of Neuroscience, University of Warwick
Nicholas Dale

Nicholas Dale gained a BA in Zoology from the University of Cambridge in 1981 and a PhD in Neuroscience from the University of Bristol 1984. He was a postdoc in Stockholm and New York, before returning to UK as a Royal Society University Research Fellow (1989) then the Royal Society Locke Research Fellow (1992). In 2000, he was appointed as the Ted Pridgeon Professor of Neuroscience at the University of Warwick and in 2015 gained a Royal Society Wolfson Research Merit Award. Other honours include an MRC Milstein Award (2007), a Scientific Medal from the Zoological Society of London (1998) and the President’s Medal of the Society for Experimental Biology (1989). Nicholas Dale made his first adenosine biosensor in 1997, which led via a tortuous path to founding Sarissa Biomedical Ltd in 2005, to make a range of state of the art biosensors available to the scientific research community and the development of clinical diagnostic biosensors. Dale has held grants from the Wellcome Trust, BBSRC, MRC, NIHR, EU FP6, Horizon2020 and the Leverhulme Trust, has published more than 100 original scientific papers and reviews, 8 patent applications, and has an H-index of 54. In addition to translational work on purine biosensors for diagnosis of stroke, he runs a blue skies research programme around two themes: how hypothalamic glial cells sense circulating nutrients and modulate the central networks that control food intake and body weight (supported by the BBSRC and MRC); and how the brain senses CO2¬ in a programme that ranges from the structural biology of the CO2 sensor (connexin26) to the physiology of breathing and blood flow (supported by the Levehulme Trust and the MRC).

Nick Housby

CEO and Director, Accunea Ltd and Precision Medicine Strategy (New Medicine Partners)
Nick Housby

Nick is a co-founder and CEO of Accunea Ltd, a medical device company with real time diagnostic monitoring products for patients with AKI and is the Director of Precision Medicine Strategy for New Medicine Partners, UK.

Nick has a PhD in Microbial Genetics from University of Warwick followed by post graduate research (genomics/biotechnology) at Harvard (DFCI, 1995) and Oxford (Biochemistry, 2000). At Oxford, the research in Professor Sir Ed Southern’s laboratory led to the creation of the spin out company Oxford Gene Technology Limited. Nick went on to secure a fellowship in technology transfer at the University of Warwick and then to Manchester as a business consultant to UMIC, mentoring entrepreneurs and commercial development of the bioincubator. This was followed by heading up the business group at Warwick HRI (2008) and the creation of Warwick Enterprise Park for provision of incubation facilities. Nick held several senior level positions as Scientist, CEO, NED, investor and Chairman in several start up enterprises such as the Oxford University start-up Oxagen (Human Genetics, 2003) Novolytics (antimicrobial therapeutics, 2010), BioMimox (peptide aptamers, 2014), Arcamis (business consulting, 2010), and has served as the Director of Business Development at OBN (2012). Nick has raised significant public, private, VC and business angel funding (Beer and Partners, 2013) for several businesses (multiple £M) and was a coach for the Growth Accelerator programme. More recently Nick created the Molecular Diagnostics Centre within the John Radcliffe Hospital, Oxford, building self-sustainability models and international collaborations and partnerships and led the successful bid to become the Oxford Genomics Medicine Centre. Nick is a current member of the Diagnostics Advisory Council in Oxfordshire; has advised on Genomics products for ThermoFisher; was a lecturer at MIB (Manchester) in genomics; and graduated (2016) with a PGDiP in Strategy and Innovation from the Said Business School in Oxford.

Owen Guy

Head of Systems Process Engineering Centre and Director, Centre for Nanohealth Engineering, Swansea University
Owen Guy

Prof. Owen J Guy (OJG) FRSC MIstP, is Head of Chemistry and Director of the Centre for Nanohealth at Swansea University; a unique facility applying device fabrication & cleanroom semiconductor processing to healthcare problems in collaboration with industry. He is a member of both the College of Science and the College of Engineering. OJG was formerly head of the Systems Process & Engineering Centre (SPEC) one of 3 research centres within of Engineering. OJG’s group has 14 years’ experience in clean room device fabrication (silicon, graphene & MEMS technology). OJG has developed graphene and microfluidics technology through EPSRC, Innovate UK projects. Owen Currently leads EPSRC and Marie Curie sensor projects at Swansea – in collaboration with Plymouth University – and a Newton fund project developing sensors for hepatitis. OJG has PI grant income of more than £4 million. OJG has published 60 papers and holds 2 granted patents (WO2011004136 and P100072GB). Owen is a Fellow of the Royal Society of Chemistry.

Peter Horvath

Group Leader, Synthetic & Systems Biology Unit and Finnish Distinguished Professor Fellow, Hungarian Academy of Sciences and Institute for Molecular Medicine Finnland
Peter Horvath

Ruth Krestin

Director Precision Medicine Business Insights & Policy, AstraZeneca
Ruth Krestin

Ruth is passionate about bringing precision medicine to patients and advancing the industry. She joined AstraZeneca’s Precision Medicine & Genomics (PMG) group in 2015 and has recently taken the lead in developing and delivering diagnostic business cases. She forecasts the downstream commercial impact of a diagnostic investment, compares alternative strategies and calculates patient access implications of diagnostic launch proposals. These business cases are used in AZ’s R&D investment decisions and support the partner selection process. Ruth was also involved in formulating and implementing AZ's company-wide genomics strategy.

Ruth has over 8 years experience as a Precision Medicine strategist, including 5 years as a consultant at PwC where she specialised in developing precision medicine and digital health business plans and opportunity evaluations for academic medical centres, pharma and diagnostic clients.

Sterghios Moschos

Associate Professor, Department of Applied Sciences, Northumbria University
Sterghios Moschos

Official Media Partner

Supporters

Workshops

Role of Molecular Diagnosis in the Development of Personalised Medicine
Workshop

Role of Molecular Diagnosis in the Development of Personalised Medicine

Holiday Inn Kensington Forum
11th July 2018
London, United Kingdom

VENUE

Holiday Inn Kensington Forum

97 Cromwell Road , London, United Kingdom

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

Molecular Dx Workshop

Download

Molecular Dx Conference Speakers

Download

Molecular Dx Conference Programme

Download

Brochure Download

Download

Media Partners


Technology Networks

Official Media Partner
http://go.technologynetworks.com/subscribe-to-newsletters

Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


Rapid Microbiology.com

Official Media Partner
http://www.rapidmicrobiology.com

rapidmicrobiology.com - keep up-to-date with all the latest products for your pharmaceutical microbiology laboratory, subscribe to the rapidmicrobiology.com newsletter http://www.rapidmicrobiology.com/Newsletter.php


Drug Target Review

Official Media Partner
http://www.drugtargetreview.com

Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


pharmanews hq

Official Media Partner
http://http://pharmanewshq.com

MedChemNet provides a unique and unparalleled platform for the medicinal chemistry community to share insights, discuss the latest research, and help move the field forward. MedChemNet covers all aspects of the drug discovery pipeline, from target identification and validation, through computer aided drug design (CADD), synthesis, screening and other biophysical techniques, to development of novel lead compounds and pre-clinical in vivo proof of concept. We also cover the design of synthetic drug delivery carriers and ADME/toxicology studies, as well as intellectual property and economic related issues. Website: Welcome to Pharma News HQ, the journal dedicated to the pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry. Pharmanewshq.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production.

Media Partners


Pharmalicensing

Supporters
http://www.pharmalicensing.com

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.


IPI

Supporters
www.ipimediaworld.com

IPI – International Pharmaceutical Industry Established by professionals with over 30 years experience in the Pharmaceutical and Life sciences publishing sectors. We have identified the needs of these dynamic industries, and have listened carefully to our readers and advertisers. With strong collaboration between Pharmaceutical and Life sciences Industry Associations we have created a global distribution network. We give you a promise to become a reliable extension of your marketing and communication arm. If necessary we will integrate our expertise with your needs. Incorporating new and innovative communication methods we will help to highlight your expertise.


Biosave

Supporters
http://www.Biosave.com

Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


Pharmaceutical-Review

Supporters
http://www.pharmaceutical-review.com

Pharmaceutical-review.com is part of Integrated IQ technologies Private Limited(IIQ). A Leading platform for all the Pharma manufacturing companies and buyers across the world.Having a subscriber database of more than 120,000 globally helping the clients to reach their target buyers through our exclusive listing, branding(banner advertisement), e-news letters, e-mail marketing, product reviews, product launch promotions, event marketing, search engine marketing and social media marketing services.


Biocompare

Supporters
http://www.biocompare.com

Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


Absave

Supporters
http://www.absave.com

Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


ASD MEDIA

Supporters
http://www.asd-network.com

Professionals in the Aerospace & Defence market use the ASD Media internet platforms to:
  • Be informed on the latest market developments; www.asd-network.com
  • Find the latest business news; www.asd-network.com
  • Find the upcoming events; www.asd-network.com
  • Find companies and organizations; www.asdsource.com
  • Distribute news globally. www.asdwire.com
The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

For more detailed information please contact with: ASD MEDIA
Stefan.koopman@asdmedia.nl


Swiss Biotech Association

Supporters
http://www.swissbiotech.org/

The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


SelectScience

Supporters
http://www.selectscience.net/register?utm_source=Media-Partner&utm_medium=Website&utm_campaign=SMI

SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover the latest drug discovery and development technologies, products and techniques with product reviews, videos, application notes and news articles. Become a member for free today.


CanBiotech

Supporters
http://www.canbiotech.com

CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


Labsave

Supporters
http://www.labsave.com

Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


European Pharmaceutical Review

Supporters
https://www.europeanpharmaceuticalreview.com/

European Pharmaceutical Contractor (EPC) is a quarterly publication dedicated to the international pharmaceutical contract market. Since its establishment in 1997, EPC has provided coverage of technical, strategic and regulatory developments within the industry. The magazine features in-depth opinion-led articles, reviews and interviews, on topics including drug development, outsourcing, pharmacovigilance, partnerships and eClinical management. Read EPC in print, online, or via the Samedan app.

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Holiday Inn Kensington Forum

97 Cromwell Road
London SW7 4DN
United Kingdom

Holiday Inn Kensington Forum

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.